New target for diagnosis, treatment of age-related macular degeneration identifedJune 15th, 2009 - 1:34 pm ICT by ANI
London, June 15 (ANI): Scientists have identified a new target for the diagnosis and treatment of age-related macular degeneration.
In a study, researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have demonstrated that blocking the activity of a specific protein - called CCR3 — can reduce the abnormal blood vessel growth that leads to macular degeneration.
Also, targeting this new protein may prove to be safer and more effective than the current treatment for the disease, which is directed at a protein called vascular endothelial growth factor or “VEGF.”
According to the researchers, the discovery - made in mouse models and cultured human cells - may also enable physicians to catch the disease in its earliest stages, before blood vessels have fully infiltrated and destroyed the central portion of the eye’s retina — an area known as the macula — to cause vision loss.
“It would be much better to prevent the disease in the first place,” said study co-author and principal investigator of the UNC study site, Mary Elizabeth Hartnett, M.D., a professor of ophthalmology in the UNC School of Medicine.
“An exciting implication of this study was that the CCR3 protein could be detected in early abnormal blood vessel growth, giving us the opportunity to prevent structural damage to the retina and preserve vision,” Hartnett added.
Age-related macular degeneration (AMD) is currently treated with drugs that block the effects of VEGF, a growth factor that promotes the growth of abnormal blood vessels.
However, because this factor is also involved in the growth and health of normal blood vessels, concerns have been raised about the safety of its long-term use. To date, however, these anti-VEGF agents have been found to be safe.
Thus, the researchers sought to identify a new target for treatment that is specific to AMD. They detected the presence of the CCR3 protein in eye tissue from humans with AMD but not in that of individuals of similar age who did not have the disease.
When they blocked CCR3, either with drugs or through genetic engineering, they saw a decrease in the generation of abnormal blood vessels.
Drugs targeting CCR3 were significantly more effective than those targeting VEGF, meaning this could represent a new therapy for the two-thirds of patients that do not respond to current treatment.
The study has been published online June 14, 2009 by the journal Nature. (ANI)
- How omega-3 fatty acids keep blindness at bay - Feb 10, 2011
- Indian origin scientist's gene therapy shows promise in slowing AMD - Apr 30, 2011
- Omega-3 in seafood may protect seniors' eyes - Dec 02, 2010
- Stem cell therapy for age-related macular degeneration may soon be a reality - Mar 25, 2011
- Novel cell therapy slows down vision loss in eye disease - Apr 08, 2011
- Age-related macular degeneration risk on the rise for Asians - May 02, 2010
- Pot-bellied men run risk of going blind - Apr 03, 2011
- Additional genes linked to age-related macular degeneration identified - Apr 13, 2010
- Red wine ingredient prevents blinding - Jun 25, 2010
- Early AMD linked to smoking, cholesterol levels - Jun 15, 2010
- Grapes can stave off age-related blindness - Jan 15, 2012
- Drugs to treat age-related blindness - Feb 07, 2011
- Vitamin A pill could protect the sight of millions - Oct 18, 2010
- Cancer drug improves vision loss in diabetics, cataract surgery patients - Aug 01, 2009
- Drug therapy shows promise in treating leading cause of childhood blindness - Feb 17, 2011
Tags: abnormal blood vessels, age related macular degeneration, blood vessel growth, central portion, chapel hill school, cultured human cells, diagnosis treatment, macula, macular degeneration, mouse models, normal blood, north carolina at chapel, north carolina at chapel hill, target, unc school, unc study, university of north carolina at chapel hill, vascular endothelial growth factor, vegf, vision loss